Abstract
No public abstract is available from the verified source records.
Caitlin Unkenholz, Esther Ortega-Vida, Jorge Monge, Christian A. Gordillo, Juan Esteban Velez-Hernandez, Divaya Bhutani, Roger Pearse, Rajshekhar Chakraborty, Suzanne Lentzsch, Ran Reshef, Mark Bustoros, Mateo Mejia Saldarriaga
Abstract
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Clinical characteristics and prognostic significance of immunoglobulin isotype switch in patients with multiple myeloma
10.1016/j.cpt.2022.11.002 · 2023
Immunoglobulin isotypes in multiple myeloma: laboratory correlates and prognostic implications in total therapy protocols
10.1111/j.1365-2141.2008.07547.x · 2009
Oligoclonal and monoclonal bands after single autologous stem cell transplant in patients with multiple myeloma: impact on overall survival and progression-free survival
10.3109/10428194.2013.873537 · 2014
Atypical serum immunofixation pattern (ASIP) development during induction therapy with BiRD for newly diagnosed multiple myeloma correlates with a high rate of complete remission
10.1182/blood.v110.11.2737.2737 · 2007
Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma
10.1111/j.1365-2141.2008.07374.x · 2008
For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission
10.1016/j.bjhh.2017.05.010 · 2017
Oligoclonal bands in patients with multiple myeloma: its emergence per se could not be translated to improved survival
10.1111/cas.12527 · 2014
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
10.1016/s0140-6736(21)00933-8 · 2021
Idecabtagene vicleucel in relapsed and refractory multiple myeloma
10.1056/nejmoa2024850 · 2021
Cilta-cel or standard care in lenalidomide-refractory multiple myeloma
10.1056/nejmoa2303379 · 2023
Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions
10.1016/j.jaip.2021.10.037 · 2022
Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians
10.1080/17474086.2022.2063833 · 2022
Clonal dysregulation of the antibody response to tetanus-toxoid after bone marrow transplantation
10.1182/blood.v84.12.4374.bloodjournal84124374 · 1994
Multiple myeloma related cells in patients undergoing autologous peripheral blood stem cell transplantation
10.1046/j.1365-2141.1999.01233.x · 1999
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma
10.1182/bloodadvances.2023012470 · 2024
Serum immunoglobulin changes in multiple myeloma patients treated with CAR T-cell therapy
10.3390/cimb47080640 · 2025
The incidence and clinical significance of monoclonal and oligoclonal protein bands in multiple myeloma patients after BCAM-CAR-T cell therapy: a retrospective study based on LEGEND-2
10.1002/hem3.70054 · 2024
Immunoglobulin isotype switch after anti-BCMA CAR T-cell therapy for relapsed or refractory multiple myeloma
10.1182/bloodadvances.2021005814 · 2022
Abnormal serum fixation patterns are a common event following BCMA CAR-T in relapsed refractory multiple myeloma and are often preceded by immunological events [abstract]
10.1016/s2152-2650(24)01957-8 · 2024
Abnormal serum fixation patterns are a common event following BCMA CAR-T therapy in relapsed refractory multiple myeloma and are often preceded by immunological events [abstract]
10.1182/blood-2024-210365 · 2024
Unresolved referenced work
2025
No additional external references are available.